were reductive metabolites. Possibly of greater importance is that they occurred as pairs of isomers with a methoxyl group substituted on a different benzene ring. This finding in the metabolism of curcuminoids is reported here for the first. In addition, the 5-dehydroxy or 5-O-methylated metabolites are also novel finding. The fact that the metabolites occurred as pairs of the isomers suggests that demethoxycurcumin possibly undergoes tautomerization between 3-keto-5-enol (form A) and 3-keto-5-enol (form B) (Fig. 1) in rats. On the basis of the metabolite profiles, metabolic pathways of demethxoycurcumin in rats are proposed.
Introduction
Curcuminoids are natural yellow pigments and food-coloring agents present in the rhizomes of the Asian tropical plant Curcuma longa which has been used as a traditional medicinal herb for thousands of years. The dried rhizome of C. longa has been widely used as an aromatic stomachic, carminative, anthelmintic, laxative, and as condiments in foods as well as for liver ailment (Nurfina et al., 1997) .
Curcuminoids are responsible for its biological actions. Curcuminoids, consist mainly of three diarylheptanoids: curcumin, demethoxycurcumin, and bisdemethoxycurcumin (Govindaajan et al., 1980) (Fig. 2) . These are recognized for their beneficial effects such as a choleretic (Ramprasad et al., 1956; Hermann et al., 1991) , as anti-oxidants (Unnikrishnan et al., 1995; Sharma, 1976) , anti-inflammatory agents (Arora et al., 1971; Ghatak et al. 1972) , for treating human immunodeficiency virus infections (Mazumber et al., 1995; Eigner et al., 1999) and as anticarcinogens (Araujo et al., 2001; Duvoix et al. 2005; Kuttan et al., 1985; Conney et al. 1991) . In recent years, their ability to protect neuronal cells from β A insult (Park et al., 2002; Kim et al., 2001 ) has also attracted great attention. Demethoxycurcumin was found to be the more effective in protecting PC12 and HUVEC cells from β A insult than curcumin. Although numerous aspects of the pharmacology of curcuminoids, in particular its activity as chemopreventive agent, have been studied, their metabolism in humans and experimental animals has not been fully characterized. The metabolism of curcumin has been studied mostly in rats in vivo and in vitro (Holder et al., 1978; Ravindranath et al., 1982; Asai et al.,1999; Pan et al., 2000; Ireson et al., 2001; Ireson et al., 2002) . More recently, information on the metabolism of curcumin in humans has been obtained from in vitro studies with hepatic and intestinal cells and subcellular fractions Ireson et al., 2002) , as well as from clinical studies in cancer patients (Cheng et al., 2001; Sharma et al., 2001; Garcea et al., 2004; Sharma et al., 2004) .
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DMD Fast Forward. Published on as DOI: 10.1124 The metabolism of demethoxycurcumin, which is the major active component in curcuminoids such as curcumin, has only been studied on one report. In that investigation, in vitro studies with tissue slices and subcellular fractions from rat liver were reported (Hoehle et al., 2006) . No data have yet been published on the metabolism of demethoxycurcumin in vivo. Therefore, studies of the metabolic products of demethoxycurcumin in feces and urine after oral administration in male Wistar rats were undertaken. The isolation and identification of nine phase 1 reductive metabolites of demethoxycurcumin are described here.
Materials and Methods
Materials. Dry rhizomes of C. Longa were collected from Gui Zhou province, China. A voucher specimen was identified by Prof. Qi-Shi Sun(No.CL200209 ) and deposited at the Department of Natural Products Chemistry, Shenyang Pharmaceutical University, China.
Demethoxycurcumin. Dry rhizomes of C. Longa(2.5kg) were pulverized then extracted 3 times for 0.5hr/each time by ultrasound in an eight-fold volume (wt/vol) of 80% EtOH. The EtOH solutions were combined and condensed to yield 362g. Then the extract was chromatographed on a silica gel column using a CHCl 3 -MeOH gradient solvent system to yield 17 fractions (Fr.A-Q). Fr.E (25.5g) was further subjected to column chromatography on a silica gel with CHCl 3 : MeOH 50:1 to yield 4 fractions (Fr.F1-Fr.F4). Demethoxycurcumin (6.8g) was obtained as a yellow-orange amorphous powder from Fr.F4 after repeated precipitation in MeOH. It had a purity of >98% according to HPLC analysis. The structure of demethoxycurcumin was identified and confirmed by comparing the MS and 1 H and 13 C NMR spectral data with those previously reported (Kiuchi et al., 1993 Animal Center (Beijing, China). Subjects were judged to be in good health and housed in conditions of temperature-(22±2℃), humidity-(55±10%), and light-(8:00-20:00) in a controlled breeding room where they were acclimated for 7 days prior to study. Normal food and water were available ad libitum, but withdrawn 24hr prior to intragastric administration of demethoxycurcumin. Demethoxycurcumin was orally administered as 30% aq. 1,2-propylene glycol solution. Urine and feces were collected for 48 hr. from animals housed in stainless steel metabolism cages equipped with a urine and feces separator.
Preliminary Studies For the sample group (four rats), a solution of demethoxycurcumin (50mg/kg) was administered orally by direct stomach intubation in a volume of 10ml/kg body weight. For the control group (four rats), the solvent 30% aq. 1,2-propylene glycol only was orally administered in rats by the same method. Pooled urine and feces of the sample group and those of the control group were simultaneously treated with parallel procedures. Urine was subjected to macroporous resin D101 3.1mg). The 50% EtOH fraction (26g) of the urine was dissolved in MeOH then filtered. The filtrate (containing spot 1 and 2) was subjected to Sephadex LH-20 column chromatography, eluted with
MeOH followed by C 18 -ODS reverse-phase open column chromatography (60% MeOH in water) to yield 7 fractions (U01-07). Further purification of U05 (containing spot 1 and 2) was performed using C 18 -ODS reverse-phase preparative HPLC (55% MeOH in water, 277nm) to afford 5 fractions (U051-U055). U055 was further subjected to C 8 -ODS reverse-phase preparative HPLC (50% MeOH in water, 284nm) to yield M-9 (1.8mg). U051 (containing spot 1 and 2) was applied to PTLC (CHCl 3 :
MeOH 15:1) to yield spot 1 ( the mixture of M-7 and M-8, 17.3mg) and spot 2 (the mixture of M-5 and M-6, 67.6mg).
Spectroscopic Methods NMR spectra were measured on Bruker ARX-300 or AV-600 spectrometers, using TMS as an internal standard. Electrospray ion trap mass spectrometry was performed on a Agilent 1100 Series LC/MSD Trap instrument whose mass range is 50 to 5000 (the mass was calibrated). The instrument was operated in the both positive and negative ion modes, using nitrogen for nebulizing and dry gas. The ionization was performed applying the following parameters: dry gas temperature, 300℃; dry gas rate: 5L/min; spray voltage, 4000V, atomization, 15psi. Sample solutions were directly introduced into the ESI source at a flow rate of 3uL/min by a syringe pump. suggested that M-1 and M-2 were the reduced metabolites of olefinic C-C double bonds of demethxoycurcumin. In the HMBC spectrum of M-2 ( (δ1.57) to C-3 (δ211.2), C-4 (δ42.9) and C-7 (δ35.3); H-6 (δ1.51) to C-4 (δ42.9), C-5 (δ23.3) and C-7 (δ35.3); H-7 (δ2.50) to C-5 (δ23.3) and C-6 (δ31.1) confirmed the presence of the moiety of 3-heptanone (group C). In addition, correlations from H-2′, H-6′ (δ6.99) to C-1 (δ28.9) justified the connectivity between the group A and group C at C1′/C1, and correlations from H-2″ (δ6.64) and H-6″ (δ6.62) to C-7 (δ35.3) revealed the junction between the group B and group C at C1″/C7 (Fig. 7) . Thus, and C-3 (δ211.2); H-2 (δ2.67) with C-3 (δ211.2); H-4 (δ2.39) with C-3 (δ211.2) and C-5 (δ23.2); H-5 (δ1.57)with C-3 (δ211.2), C-4 (δ42.9) and C-7 (δ34.7); H-6 (δ1.51) with C-4 (δ42.9), C-5 (δ23.2) and C-7 (δ34.7) and H-7 (δ2.50) with C-5 (δ23.2) and C-6 (δ31.1). Futhermore, the connectivity between the group A and group C at C1′/C1 was justified by the HMBC correlations of H-2′ (δ6.66) with C-1 were the 5-dehydroxylated products of M-5 and M-6. In addition, the MS, 1 H and 13 C-NMR data of M-5 were nearly identical with those previously reported (Kikuzaki et al., 1991) and those of M-6 were same as those previously reported (Shin et al., 2002) . Thus, M-5 and M-6 were determined to be hexahydro-demethoxycurcumin-A and hexahydro-demethoxycurcumin-B, respectively. This article has not been copyedited and formatted. The final version may differ from this version. suggested that H-1 and H-5 are three bonds away from the C-3 carbonyl group while H-2 and H-4 are adjacent to the carbonyl group. The HMBC spectrum revealed H-2′, 6′ (δ7.00) to be correlated with C-1 (δ29.0), and H-2″ (δ7.16) correlated with C-7 (δ141.9). Thus, M-9 was identified as 5-dehydroxy-dihydro-demethoxycurcumin-B. It is a 5-dehydroxy product with reduction of the double bond between C-1 and C-2 of demethoxycurcumin. The chemical shifts of M-9 were nearly identical with those previously reported (Li et al., 2004) .
HPLC Instruments
M
Discussion
This is the first study on the metabolism of demethoxycurcumin in vivo. Nine phase 1 metabolites (Hoehle et al., 2006; Holder et al., 1978; Wahlstrom et al., 1978; Ireson et al., 2001) , it might be presumed that some demethoxycurcumin should initially undergo reduction to form dihydro, tetrahydro, hexahydro (M-5 and M-6) and octahydro-demethoxycurcumin in a stepwise fashion (Ireson et al., 2002) followed by dehydroxylation (Bokkenheuser et al., 1981; Feighner et al., 1980; Kasahara et al., 1995) to form 5-dehydroxy-dihydro (M-9), 5-dehydroxy-hexahydro (M-1 and M-2) and 5-dehydroxy-octahydro-demethoxycurcumins (M-3 and M-4); on the other hand, some demethoxycurcumin might be initially methylated (Yang et al., 2005) followed by reduction to form
5-O-methyl-hexahydro-demethoxycurcumins (M-7 and M-8).
On the basis of the metabolite profiles, the metabolic pathways of demethoxycurcumin in rats are proposed (Fig. 4) .
Based on present knowledge concerning the metabolism of curcuminoids, curcuminoids as well as their reduced metabolites appear to be easily conjugated in vivo and in vitro. The reported conjugates include monoglucuronides, monosulfates, and mixed sulfate/glucuronides (Hoehle et al., 2006; Holder et al., 1978; Ravindranath et al., 1982; Asai et al., 2000) . In this study, seven new phase 1 metabolites This article has not been copyedited and formatted. The final version may differ from this version. were discovered, which provide new types of precursors for research on phase 2 metabolites of curcuminoids. In addition, because of the low bioavailability of curcumin, some previous research suggested that the pharmacological activities of curcumin was in part mediated by its metabolites Ireson et al., 2002) . This has been confirmed by recent experiments with the activities of the phase І metabolites (Murugan et al., 2006; Leyon et al., 2004; Pari et al., 2004; Limtrakul et al., 2006; Lee et al., 2005) . Further studies of the nine phase 1 reductive metabolites should clarify whether they remain the activity or not.
From the comparison of the 13 C-NMR spectra of the four pairs of isomers, it was always found that there were two very similar groups of signals and one stronger than the other. These findings suggest that, in rats, demethoxycurcumin possibly undergoes tautomerization between 3-keto-5-enol (form A) and 3-keto-5-enol (form B) ( Fig. 1) and that the forms of these two isomers were not equal, one form (form B) was the major one and that the other form (form A) was the minor one. In the HMQC spectrum of M-9, the proton signals δ H 7.40 (d, 8.6Hz ) associated with δ C 129.2 (Fig. 8 ) and δ H 3.76 with δ C 55.7 were observed in addition to the proton and carbon signals of M-9, which could be assigned to the isomer of M-9. The reason that the other correlative signals of the isomer were not entirely displayed in the 13 C and 1 H-NMR spectra of M-9 might be due to the scant amount of the compound available.
M-5 and M-6 presumably would begin to transfer partly to M-7 and M-8 when placed in MeOH for more than two weeks. However, the spot 1 (the mixture of M-7 and M-8), which was observed in TLC in the preliminary study and at that time, the urine sample had not yet been dealed with MeOH. The data demonstrated that M-7 and M-8 were the actual metabolites of demethoxycurcumin in rats. So the findings could not be validated just by LC/MS n data (Hoehleet al., 2006) . In these cases, preparation of metabolites and further identification based on NMR data must be done. Of course, the direct isolation of the metabolites from urine, bile, or feces of humans or animals has difficulties, but it is the most reliable method for the identification of metabolites.
In summary, we have determined the definitive structures of nine phase 1 reductive metabolites of demethoxycurcumin by mass spectra and NMR spectroscopy. In the urine, the major reductive metabolites are the hexahydro-demethoxycurcumin and the methyl ether products of hexahydro-demethoxycurcumin. In the feces, the dehydroxy products of hexahydro and octahydro-demethoxycurcumin are predominant. These results are important for the understanding of demethoxycurcumin metabolism in rats and should provide information and reference for the further metabolic investigation of demethoxycurcumin in humans. Screening of the bioactivities of the novel metabolite is presently under study.
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